PBH vs. IPAR, HLF, USNA, NUS, NATR, MED, VERU, EL, BAX, and SNN
Should you be buying Prestige Consumer Healthcare stock or one of its competitors? The main competitors of Prestige Consumer Healthcare include Interparfums (IPAR), Herbalife (HLF), USANA Health Sciences (USNA), Nu Skin Enterprises (NUS), Nature's Sunshine Products (NATR), MEDIFAST (MED), Veru (VERU), Estee Lauder Companies (EL), Baxter International (BAX), and Smith & Nephew SNATS (SNN).
Prestige Consumer Healthcare vs. Its Competitors
Prestige Consumer Healthcare (NYSE:PBH) and Interparfums (NASDAQ:IPAR) are both mid-cap personal products companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.
Prestige Consumer Healthcare has higher earnings, but lower revenue than Interparfums. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Interparfums, indicating that it is currently the more affordable of the two stocks.
In the previous week, Prestige Consumer Healthcare had 1 more articles in the media than Interparfums. MarketBeat recorded 4 mentions for Prestige Consumer Healthcare and 3 mentions for Interparfums. Interparfums' average media sentiment score of 1.50 beat Prestige Consumer Healthcare's score of 0.94 indicating that Interparfums is being referred to more favorably in the news media.
100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. Comparatively, 55.6% of Interparfums shares are owned by institutional investors. 1.4% of Prestige Consumer Healthcare shares are owned by insiders. Comparatively, 43.9% of Interparfums shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Prestige Consumer Healthcare has a net margin of 18.86% compared to Interparfums' net margin of 11.30%. Interparfums' return on equity of 17.62% beat Prestige Consumer Healthcare's return on equity.
Prestige Consumer Healthcare currently has a consensus target price of $93.33, indicating a potential upside of 16.70%. Interparfums has a consensus target price of $157.60, indicating a potential upside of 13.78%. Given Prestige Consumer Healthcare's higher possible upside, equities research analysts clearly believe Prestige Consumer Healthcare is more favorable than Interparfums.
Prestige Consumer Healthcare has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, Interparfums has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.
Summary
Interparfums beats Prestige Consumer Healthcare on 10 of the 16 factors compared between the two stocks.
Get Prestige Consumer Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for PBH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PBH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prestige Consumer Healthcare Competitors List
Related Companies and Tools
This page (NYSE:PBH) was last updated on 7/7/2025 by MarketBeat.com Staff
